Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Epic Bio: Epigenome editing via compact components

Horizons Ventures leads $55M series A for start-up developing compact epigenome editors with all-in-one AAV delivery

By Danielle Golovin, Staff Writer
July 13, 2022 6:42 PM UTC

Epic Bio is controlling target gene expression using single vectors that combine its highly compact Cas protein with guide RNAs and epigenetic modulators.

“Now that we’ve got the smallest Cas molecule, it opens the door to opportunities,” CEO Amber Salzman told BioCentury. Salzman, a GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) vet, was most recently president and CEO of Ohana Biosciences...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Chroma Medicine Inc.

Epicrispr Biotechnologies Inc.

Horizons Ventures

Stanford University

Tune Therapeutics Inc.

University of California

BCIQ Target Profiles

Double homeobox 4 (DUX4)